Background
==========

Administrative health insurance claims databases provide comprehensive and longitudinal records of encounters with the health care system and of drug dispensing, but lack clinical detail. For example, while the performance of a lab test will generate a claim, the test result will not be available within the claims database. This shortcoming can be overcome by merging outpatient laboratory test results extracted from electronic medical records (EMR) systems with claims data. Adjusting for lab results may result in better confounding control when administrative claims data are used to study treatment effects of medical products.

A difficulty arises from the way in which lab tests are ordered and performed in the American health care system. EMR systems with outpatient lab results generally rely on major laboratory companies to supply lab results data; results for patients whose tests are conducted outside the large chains may go unrecorded in EMRs. In conducting comparative effectiveness research in claims data, pharmacoepidemiologists generally interpret the absence of a claim as the absence of that service/diagnosis, which can result in a covariate misclassification problem but not a missing data problem \[[@B1]\]. However, missing lab test results do not mean the test was not performed or the results are normal, and thus must be handled like other missing data. There is little guidance in the literature on the nature of the missingness of such laboratory information or whether missing lab test results can be adequately imputed.

Investigators have employed varying strategies to deal with this situation. One approach is to identify a subcohort of patients with complete information on the lab test results of interest. Seeger et al. studied the effectiveness of statin therapy to reduce myocardial infarction rates, by requiring all patients studied to have a recorded LDL \> 130 mg/dl \[[@B2]\]. This approach reduces the proportion of subjects with missing data, but that advantage comes at the cost of fewer subjects in the study, and a final study population that may be dissimilar to the broader patient population for important characteristics. Furthermore, this approach is impractical for multiple unrelated lab test results, as complete cases may be few \[[@B3]\].

One unfavorable approach is to include an indicator term for missing lab test data. In the case of lab results, missingness can imply three things: (1) the physician did not see a need to have a test ordered; (2) the patient did not choose to have the test performed, or (3) the test was performed but not in a facility whose data fed back to the patient's EMR (Figure [1](#F1){ref-type="fig"}). Though the implication of each of these cases is entirely different, they are indistinguishable in the data; as such, coding them simply as "missing" would lead to bias. Even if all the missingness were due to the third case, in which data are most plausibly missing completely at random, the use of a missing indicator term could still cause bias \[[@B4],[@B5]\].

![**Reasons for missing lab test results in a longitudinal healthcare utilization database linked to a lab test provider database\*.** \* In the setting of a new user cohort study with a defined covariate assessment period before the first exposure and before follow-up](1471-2288-12-180-1){#F1}

In order to further meaningful comparative effectiveness research, we must understand the selectiveness of missing lab test results and how missingness may be related to study outcomes. In this paper, we seek to describe the analytic issues encountered when lab results may not be available for many patients. As an example, we describe the characteristics associated with the absence of laboratory test results and the degree to which missingness and actual lab test values can be predicted based on patient and health plan characteristics in a population of patients initiating lipid-lowering therapy.

Methods
=======

Database studies that combine claims and lab test results or other data from EMRs typically employ the claims as a "data backbone," as claims data provide a longitudinal view of virtually all health care encounters and drug dispensings submitted for health insurance reimbursement. Increasingly, claims databases link data from large national lab test chains \[[@B6]-[@B8]\]. Though the chains service a large number of American patients, the resulting linked data may cover substantially less than 50% of outpatient lab tests, with coverage highly dependent on the region where the patient resides and the lab companies servicing that region. Figure [1](#F1){ref-type="fig"} illustrates two levels of missingness that may arise in such situations. No claim will be recorded (Level 1) if a physician does not order a test, a patient receives a lab in a hospital, or a patient does not get a test that was ordered. The result of a test that was performed may not be transmitted to the patient's claims data (Level 2) if the insurer has not established a data exchange agreement with the laboratory provider. The likelihood of Level 2 missingness increases if there is no laboratory provider operating in the area that has a data exchange agreement with the insurer.

Data sources
------------

We employed longitudinal claims data from 14 Blue Cross and/or Blue Shield-licensed health plans of Wellpoint across 14 US states, as represented in the HealthCore Integrated Research Database^SM^ (HIRD^SM^). HealthCore linked claims information to lab test results provided by two large national laboratory providers, for laboratory tests performed between January 1, 2005 through June 30, 2010 on patients represented in the HIRD system. The claims data contained information on drug dispensings, outpatient medical services, and hospitalizations including emergency room visits. All medical services were coded with up to 9 discharge diagnoses \[[@B1]\]. Individual laboratory test results were identified by LOINC codes and standardized across lab providers. This study was approved by the Brigham and Women's Hospital Institutional Review Board and signed data use agreements were in place.

Study cohort and exposure
-------------------------

From the data available, we established a cohort of all incident users of any statin (simvastatin, pravastatin, lovastatin, atorvastatin, rosuvastatin), Vytorin (simvastatin plus ezetimibe), or ezetimibe who were 18 years or older at the start of treatment. Incident use was established by requiring at least 12 months of insurance coverage before treatment and no use of any lipid-lowering therapy in those 12 months. 1 All covariate information was assessed in the longitudinal healthcare claims over a covariate assessment period (CAP) starting 6 months before treatment initiation and up to the day of dispensing of the index drug. Follow-up for occurrence of MI started 1 month after initiation of lipid-lowering treatment, a conservative assumption to allow for the biologic action of the medication to occur (Figure [2](#F2){ref-type="fig"}) \[[@B9]\]. We categorized each medication on the index date into high and low intensity treatment based on its ability to lower LDL levels (Table [1](#T1){ref-type="table"}) \[[@B10]\].

![**Incident user cohort study\*.** \* The 6-month covariate assessment period (CAP) precedes the initiation of treatment. During the CAP we identified patient characteristics, including lab tests performed and lab test results available. After treatment start followed a 1-month lag period before events were attributed to the treatment. The arrows between prescriptions (Rx), diagnoses (Dx) and lab tests denote the fact that the temporality of events within the CAP was not considered in this study](1471-2288-12-180-2){#F2}

###### 

Definitions for high vs. low intensity lipid-lowering therapy

  **Generic entity of study medications**     **Brand name**   **High-intensity daily doses (mg)**   **Low-intensity daily doses (mg)**
  ------------------------------------------- ---------------- ------------------------------------- ------------------------------------
  Atorvastatin                                Lipitor          \> 10                                 ≤ 10
  Fluvastatin                                 Lescol           All doses considered low-intensity    
  Lovastatin                                  Mevacor          \> 40                                 ≤ 40
  Pravastatin                                 Pravachol        All doses considered low-intensity    
  Rosuvastatin                                Crestor          \> 5                                  ≤ 5
  Simvastatin                                 Zocor            \> 40                                 ≤ 40
  Ezetimibe                                   Zetia                                                   
  Ezetimibe + simvastatin fixed combination   Vytorin          If simvastatin component \> 40        If simvastatin component ≤ 40

We defined two subgroups of patients with chronic conditions. Rheumatoid arthritis (RA) was defined as at least two outpatient diagnoses of RA in the CAP or one hospital discharge diagnosis of RA in CAP or one diagnosis of RA plus dispensing of a disease modifying anti-rheumatic drug. Diabetes (DM) was defined as at least two outpatient diagnoses of DM in the CAP or one hospital discharge diagnosis of DM in CAP or one diagnosis of DM plus an insulin or oral antidiabetic dispensing. Patients with rheumatoid arthritis and diabetes were identified as subgroups with chronic conditions because these patients were likely to receive more lab tests at regular intervals than the typical patient initiating a statin. Patients with rheumatoid arthritis are of further interest in that they may receive care primarily from a specialist rather than an internist and therefore, may have different patterns of laboratory use.

Patient characteristics and lab test results
--------------------------------------------

Patient characteristics and potential confounders assessed during the 6-month CAP included age (18--40; 41--64; 65+), sex, state of residence, insurance plan type (Health Maintenance Organization, Medicare Advantage, Medicare Supplemental, Preferred Provider Organizations, Indemnity, other), number of physician visits, number of cardiologist visits, number of different drugs used, \[[@B11]\] hospitalization in the 30 days prior to treatment initiation, hospitalization for more than 30 days before treatment initiation, number of days hospitalized, number of outpatient lab test ordered, hypercholesterolemia, hypertension, heart failure, myocardial infarction, coronary revascularization, peripheral vascular disease, peripheral arterial revascularization, TIA/stroke, carotid revascularization, pre-diabetes, diabetes, arthritis, COPD, oxygen canister use, and obesity. Clinical covariates were assessed based on the presence of ICD-9 diagnosis codes (see Additional file [1](#S1){ref-type="supplementary-material"}: Appendix Table S1) in administrative claims during the CAP. In this exploratory analysis, we included a wide range of clinical covariates frequently measured in claims-based studies.

Within the 6 months covariate assessment period we identified all recorded outpatient lab test results for 23 commonly-performed lab tests, including lipid tests, Hb~A1c~, and others (see Additional file [1](#S1){ref-type="supplementary-material"}: Appendix Table S2). Additionally, we used CPT-4 codes to identify all labs for which charges were claimed during the CAP. We chose to include 23 lab tests to increase the probability that patients would have multiple lab tests performed and that we would be able to asses whether lab values were missing at the patient level or the test level.

In comparative effectiveness research, as in other areas of clinical epidemiology, missing data are both common and problematic. Imputation of missing values may increase precision and validity of effect estimates. The imputation literature recommends including not only pre-exposure patient characteristics and treatment information in the prediction of missing values but also information on the outcome status \[[@B12]\]. In our example, outcomes of interest were the incidence of myocardial infarction (assessed with a positive predictive value of 94%); \[[@B13]\] hospitalization for acute coronary syndrome (ACS) that included a coronary revascularization procedure; stroke; and death attributed to any cause (see Additional file [1](#S1){ref-type="supplementary-material"}: Appendix Table S3). Follow-up time started 1 month after initiation of a cholesterol-lowering drug (Figure [2](#F2){ref-type="fig"}). Patients were censored at the time of discontinuation of the index drug, any of the outcomes, disenrollment, or study end (June 30, 2010), whichever came first.

Analysis
--------

In this analysis, ascertainment of performing a lab test refers only to tests performed in the outpatient setting. We determined the proportion of patients who had at least one such lab test performed out of the 23 study lab tests and then focused on 3 specific cardiovascular risk markers: LDL, HDL, and Hb~A1c~\[[@B14]\]. In sensitivity analyses, we extended the 6-month covariate assessment period to 9 and to 12 months in an effort to capture more lab test results.

In order to quantify differential lab test performance and result availability, we computed the number of lab tests performed (as measured by the presence of CPT-4 codes) and the proportion of those with test results available in the linked database. We then cross-tabulated these data with patient and system characteristics.

For each of the LDL, HDL, and Hb~A1c~ cardiovascular disease risk markers, any factors associated with a completed test were identified in a multivariate logistic regression that predicted whether the outpatient lab test was performed, as a function of the patient and system characteristics described above plus statin/Vytorin exposure and cardiovascular outcome status. We then determined overall sensitivity and specificity for the predicted probabilities of test performance and model c-statistics.

In order to explore the performance of imputation strategies, we fit linear regression models for the patients who had lab test results available, in order to predict the actual LDL, HDL, and Hb~A1c~. In instances where patients received multiple tests, we used the value from the last test. We assumed normal distributions of test results as reasonable approximations, although data were slightly skewed. We express the proportion of explained variation as the observed R^2^ from the linear regression models.

Lastly, we investigated the relationship between the completion of a lab test, the availability of test results in our database, and whether the test results themselves differed between study exposure groups stratified by RA and diabetes.

Results
=======

Over the study period we identified 703,484 patients who met the study eligibility criteria and initiated lipid-lowering therapy with statins, ezetimibe, or a combination of both. Among those, 68% had a recorded charge for at least one of the 23 study lab tests in the 6 months before treatment (Table [2](#T2){ref-type="table"}). This proportion increased to 72% if the covariate assessment period was extended to 9 months before treatment, and to 74% during a 12-month period. For patients with diabetes or RA the proportions were higher (80% during 6 months) but showed equally small increases if the covariate assessment period was extended (83% and 84%). For LDL and Hb~A1c~ tests, the proportion of patients with a recorded charge for at least one test during the 6 months before initiation of lipid-lowering therapy was about 60% and 17%, respectively. For patients with diagnosed diabetes, 68% had a charge for an Hb~A1c~ test (Table [2](#T2){ref-type="table"}).

###### 

Number of patients with at least one lab test performed and claimed among 703,484 initiators of statins and/or ezetimibe using 6, 9, and 12-month confounder assessment periods (CAPs)

                  **All patients**   **Number (%) of patients with at least 1 lab test performed\***   **Number (%) of patients with at least 1 LDL lab test performed**   **Number (%) of patients with at least 1 LDL lab test performed**                                                                                                                  
  -------------- ------------------ ----------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ----- --------- ----- --------- ----- --------- ----- --------- ----- --------- ----- --------- ----- --------- -----
  All patients        703,484                                    481,133                                                              68%                                                               505,161                                72%   520,559   74%   421,708   60%   445,205   63%   460,293   65%   121,764   17%   132,358   19%   139,784   20%
  DM patients         111,684                                    89,344                                                               80%                                                               92,185                                 83%   93,952    84%   74,576    67%   78,598    70%   81,104    73%   76,413    68%   79,932    72%   81,965    73%
  RA patients          4,523                                      3,676                                                               81%                                                                3,774                                 83%    3,840    85%    2,650    59%    2,813    62%    2,915    64%     839     19%     918     20%     984     22%

\* All tests = any of a set of 23 different frequently-performed laboratory tests recorded in study database.

Overall and regardless of having a test performed, the proportion of patients with any outpatient lab test results available in the linked database was about 30%, which was similar in patients with diabetes or RA. Lab test results for LDL or HDL were available for about 20% of patients during the 6 months before initiation of lipid-lowering therapy.

Table [3](#T3){ref-type="table"} shows whether any of 23 outpatient lab tests, including LDL, HDL and Hb~A1c~ were performed within the 6 months before initiating lipid-lowering therapy cross-tabulated by a range of patient and health system characteristics. Overall, 481,133 (68%) of study patients had claims evidence of an outpatient lab test and 42% thereof had results available in the study data (29% of all patients). The proportion with at least one lab test performed varied substantially by patient characteristics, while test result availability varied little, and only for variables such as system characteristics and state of residence (Table [3](#T3){ref-type="table"}).

###### 

Patients with lab test results reported in study population of 703,484 initiators of statins or ezetimibe using a 6-month covariate assessment period\*

  **Patient characteristics as determined in CAP**                   **All patients**   **Patients with at least 1 of any 23 lab tests**^**1)**^   **Patients with at least 1 LDL test**   **Patients with at least 1 HDL test**   **Patients with at least 1 Hb**~**A1c**~**test**                                                                                                              
  ------------------------------------------------------------------ ------------------ ---------------------------------------------------------- --------------------------------------- --------------------------------------- -------------------------------------------------- ----- --------- ---- --------- ---- ----- --------- ---- --------- ---- ----- --------- ---- -------- ---- -----
  All patients                                                       703,484            481,133                                                    68                                      204,143                                 29                                                 42    421,708   60   178,254   25   42    417,598   59   176,780   25   42    121,764   17   56,653   8    47
  Age                                                                                                                                                                                                                                                                                                                                                                                             
  18-40                                                              71,396             52,674                                                     74                                      23,861                                  33                                                 45    48,565    68   21,313    30   44    48,021    67   21,150    30   44    12,424    17   5,770    8    46
  41-64                                                              489,581            363,406                                                    74                                      150,096                                 31                                                 41    329,097   67   131,999   27   40    325,945   67   130,912   27   40    92,076    19   40,635   8    44
  65+                                                                142,507            65,053                                                     46                                      30,186                                  21                                                 46    44,046    31   24,942    18   57    43,632    31   24,718    17   57    17,264    12   10,248   7    59
  Male sex                                                           378,177            256,537                                                    68                                      107,876                                 29                                                 42    225,308   60   94,715    25   42    223,007   59   93,962    25   42    66,202    18   30,286   8    46
  \# of days hospitalized                                            1                  1                                                                                                  1                                                                                                0         54   0         51   93    0         55   0         51   91    1         91   1        78   86
  Hospitalized in 30 days before treatment initiation (y/n)          52,959             29,933                                                     57                                      8,871                                   17                                                 30    15,942    30   5,738     11   36    15,929    30   5,691     11   36    6,353     12   2,483    5    39
  Hospitalized in 31 to 180 days before treatment initiation (y/n)   39,304             28,823                                                     73                                      10,569                                  27                                                 37    18,889    48   7,546     19   40    18,790    48   7,491     19   40    7,852     20   3,405    9    43
  Any coronary hospitalization\*\*                                   43,507             25,909                                                     60                                      7,468                                   17                                                 29    13,821    32   4,911     11   36    13,775    32   4,869     11   35    5,545     13   2,100    5    38
  \# of cardiologist visits                                          0                  0                                                                                                  0                                                                                                0              0                    0              0                    0              0              
  \# of other physician visits                                       3                  4                                                                                                  3                                                                                                3              3                    3              3                    4              3              
  Number of different drugs                                          4                  4                                                                                                  4                                                                                                4              4                    4              4                    6              5              
  \# of lab tests performed                                          6                  9                                                                                                  7                                                                                                9              6                    9              6                    12             8              
  **Vascular conditions:**                                                                                                                                                                                                                                                                                                                                                                        
  Hypercholesterolemia                                               358,649            308,261                                                    86                                      100,890                                 28                                                 33    286,144   80   88,027    25   31    282,875   79   87,016    24   31    74,655    21   23,200   6    31
  Hypertension                                                       351,542            244,573                                                    70                                      100,813                                 29                                                 41    207,406   59   85,722    24   41    205,531   58   84,903    24   41    75,677    22   33,388   9    44
  Heart failure                                                      16,008             10,057                                                     63                                      3,243                                   20                                                 32    5,082     32   1,917     12   38    5,064     32   1,891     12   37    2,884     18   1,089    7    38
  Acute MI                                                           20,797             11,127                                                     54                                      2,673                                   13                                                 24    5,074     24   1,709     8    34    5,046     24   1,698     8    34    1,966     9    714      3    36
  Old MI                                                             5,166              3,734                                                      72                                      998                                     19                                                 27    2,345     45   714       14   30    2,320     45   705       14   30    873       17   293      6    34
  Acute coron. syndrome                                              63,781             40,721                                                     64                                      12,776                                  20                                                 31    25,407    40   9,242     14   36    25,206    40   9,155     14   36    9,328     15   3,791    6    41
  TIA/stroke                                                         16,747             9,764                                                      58                                      3,086                                   18                                                 32    5,731     34   2,098     13   37    5,692     34   2,080     12   37    2,255     13   845      5    37
  Carotid revasc^3)^                                                 888                598                                                        67                                      193                                     22                                                 32    370       42   134       15   36    369       42   135       15   37    137       15   50       6    36
  PVD                                                                8,032              5,489                                                      68                                      1,868                                   23                                                 34    3,241     40   1,300     16   40    3,260     41   1,284     16   39    1,515     19   642      8    42
  Coronary revasc^2)^                                                22,575             13,317                                                     59                                      3,581                                   16                                                 27    7,098     31   2,377     11   33    7,069     31   2,351     10   33    2,610     12   942      4    36
  Peripheral revas                                                   987                748                                                        76                                      261                                     26                                                 35    388       39   171       17   44    394       40   170       17   43    204       21   90       9    44
  Diabetes                                                           111,684            89,344                                                     80                                      34,137                                  31                                                 38    74,576    67   28,032    25   38    73,937    66   27,693    25   37    76,413    68   26,959   24   35
  Pre-diabetes                                                       9,916              8,941                                                      90                                      2,559                                   26                                                 29    7,957     80   2,032     20   26    7,877     79   2,016     20   26    6,258     63   1,569    16   25
  Rheumatoid arthritis                                               4,523              3,676                                                      81                                      1,520                                   34                                                 41    2,650     59   935       21   35    2,620     58   926       20   35    839       19   315      7    38
  Recorded obesity                                                   20,533             17,354                                                     85                                      5,295                                   26                                                 31    15,138    74   4,307     21   28    14,971    73   4,251     21   28    6,897     34   1,956    10   28
  COPD                                                               27,318             18,918                                                     69                                      6,382                                   23                                                 34    13,236    48   4,855     18   37    13,144    48   4,818     18   37    4,557     17   1,708    6    37
  Use of oxygen tank                                                 105                59                                                         56                                      20                                      19                                                 34    41        39   13        12   32    42        40   13        12   31    20        19   8        8    40
  **Plan type:** Indemnity                                           3,942              3,391                                                      86                                      807                                     20                                                 24    3,149     80   696       18   22    3,132     79   698       18   22    823       21   181      5    22
  HMO                                                                202,910            109,821                                                    54                                      100,426                                 49                                                 91    95,306    47   92,427    46   97    94,360    47   91,683    45   97    28,471    14   30,241   15   106
  Medicare Advantage                                                 62,459             37,744                                                     60                                      24,757                                  40                                                 66    28,014    45   20,468    33   73    27,758    44   20,304    33   73    11,658    19   8,622    14   74
  Medicare Supplemental                                              43,645             15,519                                                     36                                      1,294                                   3                                                  8     7,822     18   1,000     2    13    7,745     18   994       2    13    2,647     6    285      1    11
  Other                                                              22,274             10,323                                                     46                                      4,057                                   18                                                 39    8,677     39   3,486     16   40    8,593     39   3,456     16   40    2,422     11   1,153    5    48
  Preferred Provider Org.                                            368,254            304,335                                                    83                                      72,802                                  20                                                 24    278,740   76   60,177    16   22    276,010   75   59,645    16   22    75,743    21   16,171   4    21
  **State of residence:** 1                                          194,150            97,286                                                     50                                      51,523                                  27                                                 53    83,875    43   46,332    24   55    82,694    43   46,342    24   56    25,050    13   16,146   8    64
  2                                                                  23,642             20,159                                                     85                                      9,281                                   39                                                 46    18,674    79   8,517     36   46    18,678    79   8,521     36   46    5,416     23   2,352    10   43
  3†                                                                 5,006              3,783                                                      76                                      359                                     7                                                  9     3,420     68   318       6    9     3,395     68   311       6    9     923       18   85       2    9
  4                                                                  64,242             53,997                                                     84                                      30,197                                  47                                                 56    49,458    77   27,231    42   55    48,892    76   26,855    42   55    13,198    21   7,569    12   57
  5                                                                  36,365             29,200                                                     80                                      4,805                                   13                                                 16    25,522    70   3,635     10   14    25,903    71   3,604     10   14    6,872     19   917      3    13
  6                                                                  48,045             37,348                                                     78                                      8,630                                   18                                                 23    32,056    67   6,583     14   21    31,752    66   6,476     13   20    8,929     19   1,723    4    19
  7                                                                  13,847             11,833                                                     85                                      359                                     3                                                  3     10,773    78   260       2    2     10,647    77   259       2    2     2,678     19   44       0    2
  8                                                                  28,450             23,108                                                     81                                      6,178                                   22                                                 27    20,781    73   5,309     19   26    20,627    73   5,276     19   26    5,877     21   1,461    5    25
  9                                                                  8,703              7,401                                                      85                                      1,089                                   13                                                 15    6,789     78   875       10   13    6,772     78   886       10   13    1,812     21   243      3    13
  10†                                                                3,753              2,464                                                      66                                      1,183                                   32                                                 48    2,226     59   1,097     29   49    2,188     58   1,083     29   49    710       19   369      10   52
  11                                                                 4,864              3,610                                                      74                                      2,310                                   47                                                 64    3,217     66   2,030     42   63    3,137     64   2,029     42   65    1,015     21   648      13   64
  12                                                                 64,237             24,644                                                     38                                      36,009                                  56                                                 146   15,190    24   32,988    51   217   14,979    23   32,722    51   218   6,068     9    12,646   20   208
  13                                                                 85,926             71,455                                                     83                                      22,481                                  26                                                 31    63,065    73   18,108    21   29    62,703    73   17,993    21   29    19,587    23   5,464    6    28
  Other                                                              44,110             35,064                                                     79                                      5,628                                   13                                                 16    31,850    72   4,867     11   15    31,462    71   4,839     11   15    8,949     20   1,446    3    16
  14†                                                                3,804              3,311                                                      87                                      116                                     3                                                  4     3,113     82   100       3    3     3,107     82   99        3    3     876       23   31       1    4
  15                                                                 74,340             56,470                                                     76                                      23,995                                  32                                                 42    51,699    70   20,004    27   39    50,662    68   19,485    26   38    13,804    19   5,509    7    40

\* Study period starts July 1, 2005, ensuring a minimum CAP of 6 months with lab test results coverage and a pre-CAP of 6 months.

\*\* Hospitalization with primary discharge code for acute MI, ACS, PCTA, PCI, CABG.

† States with no WellPoint presence.

1\) This is limited to 23 lab test results reported in our study database.

2\) PCTA, PCI, CABG.

3\) Carotid stent, carotid endarterectomy.

Having been hospitalized in the 30 days before the initiation of lipid-lowering treatment was negatively associated with receiving an outpatient test, likely because the relevant lab tests were performed during the hospitalization and as such do not appear as outpatient lab tests. Some patients hospitalized for acute coronary syndrome or MI may have received lipid-lowering therapy for secondary prevention without the need for a lab test. This is supported by the fact that patients with both recent MI and ACS had a lower than average proportion with at least one test performed (24% and 40% compared with an average of 68%). A code for hypercholesterolemia is frequently accompanied by an LDL test performed (80%) likely because the test ordering is accompanied with such a billing code.

Patients with Medicare Supplemental coverage (43,645) had a much lower proportion of claims for LDL tests performed (18%), and of those only 2% had results available. The lab test provider may not have included the secondary payer on the claim.

The two lab test providers that provided data to the insurer do not operate in some states; for example, the availability of lab test results in one state was as low as 2% for LDL. Such low recording would not be dependent directly on patient characteristics as it affects an entire state and is driven by factors other than health status, though clinically relevant patient characteristics have varying prevalences across states.

Some patients resided in states not primarily covered by the health plan studied, and are covered only via accounts for nationally operating businesses (e.g., if the employer is based in another state, all employees may be members of a health plan in that other state, rather than the state of residence). For these patients, the availability of LDL test results is less than 10%. One state (\#12) stands out as having a small proportion of patients with an outpatient LDL test performed (24%), but a much larger proportion of patients have a result available (51%). In this state, a larger proportion of providers are under HMO capitation agreements. Within these plans, under-recording of tests performed may be the result of bundled payment arrangements; however, results are still forwarded by the lab test providers resulting in the paradox of having more lab test results available in our database than performed as recorded in claims data. Among patients with Diabetes or RA, we found fundamentally similar results. Among elderly patients lab test results were more likely to be available among Medicare advantage enrollees than those patients covered through Medicare supplemental insurance (Table [4](#T4){ref-type="table"}).

###### 

Cross-tabulation between states and Medicare Advantage and Medicare Supplement status

          **Patients with at least 1 of any 23 lab tests**^**1)**^                                                                                      
  ------- ---------------------------------------------------------- ---- -------- ---- ----- -------- ---- -------- ----- ----- ------- ---- ----- --- ----
  1       87,110                                                     52   48,838   29   56    3,999    51   1,978    25    49    5,881   31   625   3   11
  2       17,068                                                     89   8,331    43   49    174      85   95       46    55    574     37   92    6   16
  3†      3,507                                                      81   329      8    9     16       44   12       33    75    141     39   3     1   2
  4       53,350                                                     86   30,037   48   56    112      84   64       48    57    519     26   92    5   18
  5       26,240                                                     84   4,454    14   17    1,036    80   167      13    16    999     38   55    2   6
  6       30,291                                                     86   7,265    21   24    2,850    79   1,139    32    40    4,012   45   185   2   5
  7       11,050                                                     89   346      3    3     0        0    1        100   0     564     47   6     1   1
  8       22,277                                                     85   6,068    23   27    4        14   7        24    175   692     34   71    3   10
  9       6,449                                                      89   1,003    14   16    0        0    0        0     0     278     40   8     1   3
  10†     2,372                                                      66   1,144    32   48    3        23   5        38    167   5       31   0     0   0
  11      3,547                                                      76   2,289    49   65    1        33   2        67    200   38      21   9     5   24
  12      15,645                                                     43   19,387   54   124   6,560    30   14,189   65    216   105     39   15    6   14
  13      46,115                                                     86   15,049   28   33    22,884   84   7,035    26    31    1,543   39   126   3   8
  Other   32,651                                                     81   5,515    14   17    54       39   54       39    100   153     37   5     1   3
  14†     3,256                                                      88   113      3    3     0        0    0        0     0     7       30   0     0   0
  15      53,228                                                     82   23,060   36   43    51       59   9        10    18    8       33   2     8   25

† States with no WellPoint presence.

Based on patient and system characteristics plus exposure and outcome status it was possible to predict with high sensitivity (97%) and specificity (94%) whether outpatient lab tests were performed in the 6 months before treatment initiation. The corresponding model c-statistics of the logistic regression models were between 0.89 and 0.93 (Figure [3](#F3){ref-type="fig"}), indicating a very high predictive capacity. Strong independent associates of having an outpatient LDL test performed were a diagnosis of hypercholesterolemia or obesity, and carotid revascularization. Associates of low probability of doing LDL lab tests were recent hospitalization and being diagnosed with RA. Being older than 65 also decreased the chance of an LDL lab test, likely because of test underreporting due to bundled payments. Initiating high-intensity lipid-lowering treatment and dying in the study follow-up period were correlates of not having an outpatient LDL, HDL, or HB~A1c~ test performed. Not surprisingly, the strongest predictor of having an HB~A1c~ test performed was a diagnosis of diabetes or pre-diabetes.

![Associates of selected outpatient lab tests performed in patients initiating lipid-lowering treatment according to claims data in 703,484 patients from a logistic regression model (darker means stronger association)](1471-2288-12-180-3){#F3}

Among the patients for whom LDL, HDL, or HB~A1c~ test levels were available, we then attempted to predict the actual lab levels based on their recorded patient and system characteristics. Using all observed factors described above, 17% of the variation could be explained (Figure [4](#F4){ref-type="fig"}). Young age was the strongest correlate of increased high LDL (+20 mg/dl) and Hb~A1c~ (+0.5%) levels, suggesting that in younger age initiation of lipid-lowering therapy was more driven by lab test results, i.e. primary prevention, while in older age past coronary events and other risk factors were the triggers for statin initiation despite lower LDL levels (−17 mg/dl).

![Correlates of selected lab test results among patients with lab test results available (darker means stronger correlations)](1471-2288-12-180-4){#F4}

Higher intensity of lipid lowering treatment generally was correlated with a lower proportion of outpatient LDL tests performed, a lower fraction of LDL test results available in the database, and lower LDL serum levels (Table [5](#T5){ref-type="table"}). For example, among high dose simvastatin initiators (\>40 mg/day), 52% had an outpatient LDL test performed before treatment start (63% for lower dose simvastatin). Of those patients, 37% had a test result available (42%), and the mean LDL serum level was 135.6 mg/dl compared to 147.3 mg/dl for patients started on low-intensity simvastatin. Mean LDL levels were generally lower in patients with diabetes who initiated lipid-lowering therapy.

###### 

LDL tests performed and LDL test results available by lipid lowering treatment in patients initiating lipid-lowering therapy, including patient subgroups with diabetes (DM) or rheumatoid arthritis (RA)

                                              **All patients**   **LDL test performed**   **LDL test results available**   **LDL level**   **HDL level**                                       
  ----- ------------------------------------- ------------------ ------------------------ -------------------------------- --------------- --------------- ------ ------ ------- ------ ------ ------
  All   Any statin alone                      655,211            93                       395,496                          60.4            165,380         25.2   41.8   145.3   38.6   50.2   14.5
        Any statin high intensity\*           173,979            25                       98,309                           56.5            41,320          23.7   42.0   144.2   45.5   49.2   14.3
        Any statin low intensity              481,232            68                       297,187                          61.8            124,060         25.8   41.7   145.7   36     50.6   14.6
        Simvastatin alone                     282,658            40                       176,697                          62.5            73,193          25.9   41.4   147.0   36.3   50.2   14.4
        Simvastatin high dose (\>40 mg)       11,354             2                        5,912                            52.1            2,192           19.3   37.1   135.6   49.5   48     13.6
        Simvastatin low dose                  271,304            39                       170,785                          62.9            71,001          26.2   41.6   147.3   35.8   50.2   14.4
        Vytorin alone                         24,931             4                        12,966                           52              6,820           27.4   52.6   142.2   47.6   49.6   14.3
        Vytorin high dose (\>40 mg simvast)   1,069              0                        563                              52.7            223             20.9   39.6   124.1   56.7   48.1   13.5
        Vytorin low dose                      23,862             3                        12,403                           52              6,597           27.6   53.2   142.8   47.1   49.6   14.4
        Ezetimibe alone                       20,509             3                        11,412                           55.6            5,334           26     46.7   143.2   38.1   51.5   14.9
        Ezetimibe + statin                    2,833              0                        1,834                            64.7            720             25.4   39.3   145.7   47.7   48.2   13.5
        **Total:**                            **703,484**                                                                                                                                       
  DM    Any statin alone                      103,664            93                       69,788                           67.3            25,927          25     37.2   124.8   37.4   46.5   13.1
        Any statin high intensity\*           28,472             26                       18,069                           63.5            6,909           24.3   38.2   122.3   43.3   45.8   13.1
        Any statin low intensity              75,192             67                       51,719                           68.8            19,018          25.3   36.8   125.7   35.0   46.8   13.1
        Simvastatin alone                     46,414             42                       32,207                           69.4            11,670          25.1   36.2   126.8   35.6   46.5   13.0
        Simvastatin high dose (\>40 mg)       2,498              2                        1,513                            60.6            521             20.9   34.4   117.1   46.2   45.6   12.6
        Simvastatin low dose                  43,916             39                       30,694                           69.9            11,149          25.4   36.3   127.2   35.0   46.6   13.0
        Vytorin alone                         4,049              4                        2,324                            57.4            1,086           26.8   46.7   122.9   44.4   45.6   13.4
        Vytorin high dose (\>40 mg simvast)   269                0                        169                              62.8            58              21.6   34.3   105.6   41.6   46.3   14.0
        Vytorin low dose                      3,780              3                        2,155                            57              1,028           27.2   47.7   123.8   44.4   45.6   13.4
        Ezetimibe alone                       3,459              3                        2,092                            60.5            884             25.6   42.3   126.9   37.7   47.0   13.1
        Ezetimibe + statin                    512                1                        372                              72.7            135             26.4   36.3   133.1   44.5   44.8   11.8
        **Total:**                            **111,684**                                                                                                                                       
  RA    Any statin alone                      4,118              91                       2,425                            58.9            833             20.2   34.4   138.5   39.4   54.7   16.5
        Any statin high intensity\*           1,044              23                       575                              55.1            205             19.6   35.7   135.4   50.9   53.6   17.8
        Any statin low intensity              3,074              68                       1,850                            60.2            628             20.4   33.9   139.5   34.8   55.1   16.0
        Simvastatin alone                     1,749              39                       1,070                            61.2            360             20.6   33.6   141.6   33.4   54.3   15.5
        Simvastatin high dose (\>40 mg)       70                 2                        37                               52.9            14              20     37.8   134.6   44.2   46.5   12.0
        Simvastatin low dose                  1,679              37                       1,033                            61.5            346             20.6   33.5   141.9   32.9   54.6   15.6
        Vytorin alone                         174                4                        85                               48.9            43              24.7   50.6   142.6   45.6   52.8   16.3
        Vytorin high dose (\>40 mg simvast)   9                  0                        4                                44.4            2               22.2   50.0   177.0   76.4   52     22.6
        Vytorin low dose                      165                4                        81                               49.1            41              24.8   50.6   141.0   44.5   52.8   16.3
        Ezetimibe alone                       210                5                        126                              60              55              26.2   43.7   137.5   31.3   56.8   16.7
        Ezetimibe + statin                    21                 1                        14                               66.7            4               19     28.6   144.0   45.5   49.0   10.4
        **Total:**                            **4,523**                                                                                                                                         

\* See methods section for definition.

Discussion
==========

We studied the characteristics of laboratory test information in a pharmacoepidemiologic research data source that enriches longitudinal claims data with outpatient lab test results data, which makes it possible to better adjust for biomarkers of cardiac risk in comparative effectiveness studies. In an example cohort study of 703,484 patients initiating various lipid-lowering therapies, 68% of patients had at least one of a set of 23 study lab tests performed in the 6 months before treatment, and 42% of those had test results available. LDL test results were available for 24% of statin initiators, a non-trivial level of missingness that needed to be addressed in order to preserve the validity and generalizability of findings. Missingness due to absence of lab tests being performed followed a complex pattern that is largely explained by hospitalization, clinical practice guidelines which differ for primary and secondary prevention of coronary heart disease, and by some health care system characteristics.

Several key points regarding these patterns arose and have implications for conducting comparative effectiveness research studies in such enriched data sources.

Operational aspects
-------------------

A covariate assessment period of 6 months was sufficient to capture the majority of outpatient lab tests performed. Extending the period to 9 and 12 months, and thus extending the required pre-exposure enrollment period, provided few additional observed lab tests but may disproportionally reduce the cohort size if working with health plans that have high enrollee turnover rates. Patients with existing chronic conditions like RA or diabetes have more outpatient lab tests available if their healthcare providers monitor them more closely. Recent hospitalizations strongly decreased the number of outpatient lab tests. It is likely that tests were performed during the hospitalization, and if the test results were available to the patient\'s primary care physician, repeating testing may not have been required for some time after discharge.

Selectiveness of lab tests performed
------------------------------------

Patients with risk factors for cardiovascular events were less likely to have lab tests performed. Many patients with these characteristics receive lipid-lowering treatment as secondary prevention, which is initiated independent of serum lipid-levels more frequently than is primary prevention. Indeed, treatment guidelines in place since the late 1990s recommend that patients with a major cardiac event should be treated with lipid lowering medications \[[@B15],[@B16]\]. In a prior study, patients who initiated high-intensity lipid-lowering treatment were less likely to have had an outpatient lab test performed \[[@B17]\]. Because the presence of preexisting cardiac risk factors is both a strong predictor of future events and a predictor of missing data on lipid levels, disregarding the missing information can be expected to bias findings of non-randomized comparative effectiveness research in this setting.

Selectiveness of lipid lab test results available
-------------------------------------------------

Among patients who had lab test result available, those who were subsequently initiated on higher-intensity lipid-lowering treatment were more likely to have lower lipid serum levels. This finding is again compatible with clinical practice and trial findings that patients with acute coronary events (who are less likely to have outpatient lipid tests available) should be treated with high-intensity statins largely independent of their lipid levels \[[@B17],[@B18]\]. System factors like state of residence and insurance plan type, particularly supplemental insurance, may substantially influence the availability of test results. However, since those factors are less likely to be systematically related to health outcomes it is unlikely that these will act as major confounding factors in comparative effectiveness studies.

In addition to these limitations regarding lab tests, baseline clinical conditions may be under-reported through claims data in some patients, particularly when using a short ascertainment period, such as the 6-month period we used. For LDL, HDL, and HB~A1c~ tests it is unlikely that point-of-care testing would be performed, which the lab test provider chain would not record. However, other tests, like INR, urine analyses and creatinine levels might be subject to this additional limitation.

If replicated in other patient populations and datasets, these findings have important implications for CER studies. The complexity of the nature of missingness that logically follows from clinical practice and the reality of our health care system requires the inclusion of a wide variety of patient and system characteristics in order to model the missing data structure. In our specific example the combination of primary and secondary prevention with lipid-lowering medications seems to complicate the prediction of missing values, but in the end is likely a reason why we could differentiate so well between patients who have an outpatient LDL test performed versus not (Figure [5](#F5){ref-type="fig"}). Once the outpatient lab test results were available, we had moderate ability to predict the exact lipid/Hb~A1c~ serum level. The resulting mismeasurement of imputed lab test results suggests that imputation of test results would provide only limited additional confounding control. However, estimation precision would be increased because the analyzable population would more than triple in our example study.

![**Ability of longitudinal claims data to predict whether a lab test was performed, a test result was available, and the actual serum level for three biomarkers of cardiovascular risk\*.** \* c-statistics were computed from multivariate logistic regression models including patient factors measured during 6 months before lipid-lowering treatment initiation; r^2^ measured were computed only among patients who had a lab test result available from linear regression including patient factors measured during 6 months before lipid-lowering treatment initiation, actual treatment choice, as well as cardiovascular events and death during follow-up](1471-2288-12-180-5){#F5}

It is likely that the specific patterns of missingness of outpatient lab test results will vary depending on the clinical scenario, health care practice, and system constraints. It is encouraging that despite the non-random missingness we were able to predict quite well who would and would not receive a lab test result, which is a good starting point for addressing this issue. However, our difficulty in predicting actual lab values is a challenge to incorporating lab data through imputation or weighting approaches in comparative effectiveness research studies.

Conclusion
==========

In a claims database linked with outpatient lab test results, we found that lab tests are performed selectively depending on patient risk factors and corresponding to current treatment guidelines. Poor ability to predict lab values and the high proportion of missingness reduces the added value of lab tests for effectiveness research in this setting.
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